This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of other endocrine glands and related structures
C3_ENDOCRINE_NAS
endocrine neoplasm: A benign or malignant neoplasm arising from the epithelial cells of an endocrine organ. Representative examples include pituitary gland adenoma, pituitary gland carcinoma, thyroid gland carcinoma, carcinoid tumor, and neuroendocrine carcinoma.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
69 |
4. Check minimum number of eventsNone |
69 |
5. Include endpointsNone |
69 |
6. Filter based on genotype QC (FinnGen only) |
66 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other endocrine glands and related structures
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of other endocrine glands and related structures, including Hilmo
- Malignant neoplasm of endocrine gland
- Malignant neoplasm of endocrine gland, including Hilmo
- Solid cancers
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 66 | 33 | 33 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.02 |
| Median age at first event (years) | 54.55 | 50.92 | 58.18 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 68
- Matched controls
- 680
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C75.0
ICD-10 Finland
Malignant neoplasm: Parathyroid gland
+∞
33.0
29
*
8010/3-C75.0
ICD-O-3
Carcinoma, NOS, of parathyroid gland
+∞
25.6
23
*
130
Kela drug reimbursment
Malignant tumour
+∞
24.4
22
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
170.0
23.2
23
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
21.0
15.5
23
16
8680/3-C75.5
ICD-O-3
Paraganglioma, NOS, of aortic body and other paraganglia
+∞
15.2
14
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
14.0
13
*
BBA40
NOMESCO Finland
Subtotal parathyroidectomy
173.2
14.0
14
*
H02AB09
ATC
hydrocortisone; systemic
41.0
13.3
16
5
BAA40
NOMESCO Finland
Unilateral lobectomy of thyroid gland
37.7
12.2
15
5
WX408
NOMESCO Finland
General anesthesy, balanced
5.9
11.8
32
89
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
143.3
11.8
12
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
52.7
11.4
13
*
WX402
NOMESCO Finland
General anaesthesia
5.8
11.2
30
82
H02AB02
ATC
dexamethasone; systemic
71.6
11.0
12
*
E83.50
ICD-10 Finland
Hypercalcemia
71.6
11.0
12
*
XX3DW
NOMESCO Finland
Time consuming IT work
20.4
11.0
16
10
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
129.1
10.7
11
*
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
47.7
10.3
12
*
H03AA01
ATC
levothyroxine sodium; systemic
5.2
10.2
31
94
A03FA01
ATC
metoclopramide; systemic, rectal
6.2
9.9
21
46
WX404
NOMESCO Finland
Intravenous generell anesthesy
5.4
8.9
22
55
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
102.2
8.6
9
*
JN4AD
NOMESCO Finland
Body CT examination
14.3
8.5
14
12
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
8.5
8
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
8.5
8
*
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
8.5
8
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
38.4
8.3
10
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
28.8
7.8
10
*
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
28.8
7.8
10
*
ZXE10
NOMESCO Finland
More than one and less than three hours
4.1
7.6
35
140
8272/3-C75.1
ICD-O-3
Pituitary carcinoma, NOS, of pituitary gland
+∞
7.4
7
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
7.4
7
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
44.6
6.9
8
*
Z31.5
ICD-10 Finland
Genetic counselling
14.3
6.9
11
9
ZXE20
NOMESCO Finland
More than three and less than five hours
5.1
6.8
17
42
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
12.8
6.6
11
10
BB1BQ
NOMESCO Finland
Extensive scintigraphy of parathyroid gland, 2 isotopes, SPECT and low-dose CT
76.8
6.5
7
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
6.3
6
*
D35.59
ICD-10 Finland
Other paragangliom
+∞
6.3
6
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
+∞
6.3
6
*
L01AX03
ATC
temozolomide; systemic
+∞
6.3
6
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
6.3
6
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
6.3
6
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
6.3
6
*
8140/3-C75.0
ICD-O-3
Adenocarcinoma, NOS, of parathyroid gland
+∞
6.3
6
*
WF002
NOMESCO Finland
Radical radiotherapy
+∞
6.3
6
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.3
6.3
20
60
A11CC03
ATC
alfacalcidol; systemic
17.0
6.1
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
33
71
8.09
16.62
11.4
5.2
0.97
1.01
mmol/l
0.20
33
64
24
51
6.73
11.79
4.8
2.7
—
—
—
0
0
57
273
7.73
10.94
24.5
6.6
1.23
1.21
mmol/l
0.53
44
245
9
0
+∞
9.59
4.2
0.0
—
—
—
0
0
10
10
11.47
5.75
4.1
4.9
5.86
12.31
pmol/l
—
10
10
24
90
3.58
5.48
1.8
1.4
—
—
—
0
0
8
7
12.72
4.92
1.1
1.0
—
—
—
0
0
43
241
3.13
4.91
4.1
2.4
—
—
estimate
—
0
0
9
11
9.22
4.72
1.2
1.1
—
—
—
0
0
15
39
4.64
4.56
13.7
11.3
24.83
24.79
mmol/l
0.02
15
39
7
6
12.79
4.38
1.1
1.2
—
—
—
0
0
8
10
8.88
4.18
4.6
1.3
—
—
—
0
0
14
43
3.84
4.18
11.9
14.4
96.13
91.74
%
2.07
14
43
6
6
10.80
3.57
7.0
1.7
3.12
1.80
u/ml
—
6
6
20
88
2.80
3.34
6.7
2.4
11.69
13.58
umol/l
0.63
20
80
25
124
2.61
3.31
3.4
2.0
—
—
—
0
0
12
35
3.94
3.31
2.0
1.3
—
—
—
0
0
18
78
2.78
3.07
7.2
2.4
2.26
2.32
g/l
0.15
18
70
5
5
10.64
3.02
2.0
1.4
—
—
—
0
0
16
67
2.82
2.89
1.9
1.3
—
—
—
0
0
12
41
3.33
2.80
13.1
14.9
0.39
0.63
%
1.98
12
41
10
33
3.37
2.48
2.0
1.2
—
—
—
0
0
13
54
2.74
2.37
20.4
11.4
1.04
1.34
mmol/l
0.87
13
54
48
356
2.18
2.22
12.1
4.9
6.54
6.83
mmol/l
0.71
48
335
14
63
2.54
2.19
2.1
1.3
—
—
—
0
0
17
85
2.33
2.13
2.3
1.6
1535.33
1027.47
nmol/l
0.72
12
66
7
20
3.78
2.12
3.7
2.8
24.31
24.74
mmol/l
—
7
20
6
15
4.28
2.09
1.5
1.9
80.00
95.13
%
—
6
15
28
175
2.02
2.01
2.2
2.1
528.89
222.68
u/l
0.48
28
168
5
12
4.40
1.85
1.0
1.2
—
—
—
0
0
25
155
1.97
1.81
3.2
3.5
0.00
0.00
estimate
-0.00
16
53
5
13
4.06
1.74
1.6
2.0
157.00
204.31
%
—
5
13
5
13
4.06
1.74
2.0
2.9
2.86
4.60
g/l
—
5
13
10
43
2.55
1.67
15.1
14.4
0.86
1.64
%
—
10
43
0
45
0.00
1.57
0.0
2.4
—
—
—
0
0
15
82
2.06
1.50
22.0
9.0
104.00
104.83
mmol/l
0.41
15
82
6
23
2.76
1.40
1.2
1.5
—
—
—
0
0
0
38
0.00
1.39
0.0
2.2
—
—
—
0
0
5
17
3.09
1.38
1.8
1.2
681.00
420.94
mg/l
—
5
17
6
24
2.64
1.33
1.2
1.6
—
—
—
0
0
34
253
1.69
1.28
1.6
2.1
1.66
1.36
mmol/l
0.78
26
216
17
105
1.83
1.20
1.8
1.7
438.67
450.79
pmol/l
0.06
12
87
41
327
1.64
1.14
3.0
3.6
0.00
0.00
estimate
-0.00
15
53
5
21
2.49
1.11
1.0
1.2
—
—
—
0
0
5
22
2.37
1.05
1.0
1.2
—
—
—
0
0
40
322
1.59
1.03
3.0
3.5
0.00
0.00
estimate
-0.00
16
58
7
127
0.50
1.01
1.4
2.0
—
—
—
0
0
6
28
2.25
0.94
1.3
1.3
—
—
—
0
0
5
95
0.49
0.86
2.0
2.8
—
—
—
0
0
39
321
1.50
0.85
3.0
3.5
0.00
0.00
estimate
-0.00
16
59
7
39
1.88
0.75
26.4
3.7
26.29
24.22
mmol/l
—
7
39
28
220
1.46
0.74
4.9
4.5
20.91
8.56
mg/mmol
0.46
20
146
5
30
1.72
0.62
1.6
3.2
24.06
25.29
mmol/l
—
5
30
44
384
1.41
0.62
3.0
3.6
—
—
—
0
0
5
88
0.53
0.61
2.0
2.6
—
—
—
0
0
0
22
0.00
0.60
0.0
1.4
—
140.42
—
0
12
6
36
1.73
0.58
21.0
2.6
0.72
1.56
%
—
6
36
0
15
0.00
0.42
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
6
42
1.47
0.37
1.2
1.2
—
—
—
0
0
10
74
1.41
0.34
1.3
1.5
—
—
—
0
0
22
188
1.25
0.31
3.0
3.0
0.00
0.00
estimate
-0.00
14
45
13
105
1.29
0.27
3.2
2.5
0.83
0.67
ug/l
—
8
63
61
590
1.33
0.24
4.6
5.2
1.40
1.44
mmol/l
0.32
56
545
5
39
1.30
0.23
1.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
27
246
1.16
0.18
3.2
3.4
0.00
0.00
estimate
-0.00
14
44
61
598
1.19
0.07
5.5
6.0
2.69
2.71
mmol/l
0.06
56
555
56
568
0.92
0.03
4.0
4.4
1.45
1.29
mmol/l
0.70
50
519
28
272
1.05
0.02
2.3
2.0
93.51
96.93
pmol/l
0.19
17
139
13
124
1.06
0.01
3.7
3.5
20.38
419.32
ng/l
1.00
13
91
16
154
1.05
0.00
5.0
3.4
23.27
24.87
%
—
6
61
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
63
626
1.09
-0.00
19.8
9.7
26.57
26.81
u/l
0.05
58
607
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
6
65
0.92
-0.00
12.2
5.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_ENDOCRINE_NAS – Malignant neoplasm of other endocrine glands and related structures
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).